PE03242003A1 - pharmaceutical compositions of amlodipine and atorvastatin - Google Patents

pharmaceutical compositions of amlodipine and atorvastatin

Info

Publication number
PE03242003A1
PE03242003A1 PE0006662002A PE0006662002A PE03242003A1 PE 03242003 A1 PE03242003 A1 PE 03242003A1 PE 0006662002 A PE0006662002 A PE 0006662002A PE 0006662002 A PE0006662002 A PE 0006662002A PE 03242003 A1 PE03242003 A1 PE 03242003A1
Authority
PE
Peru
Prior art keywords
component
atorvastatin
composition
amlodipine
refers
Prior art date
Application number
PE0006662002A
Other languages
Spanish (es)
Inventor
Laman Alani
Sadath Ulla Khan
Nouman Abdul-Hussain Muhammad
Thomas Michael Macneil
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US30913301P priority Critical
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE03242003A1 publication Critical patent/PE03242003A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) UNA GRANULACION DE ATORVASTATINA O SUS SALES FARMACEUTICAMENTE ACEPTABLES Y UN VEHICULO QUE INCLUYE UN AGENTE ALCALINIZANTE QUE FORMA UN pH MAYOR A 5; It refers to a pharmaceutical composition comprising: a) a granulation of atorvastatin or pharmaceutically acceptable salts thereof and a carrier including an alkalizing agent that forms a pH greater than 5; b) UN SEGUNDO COMPONENTE QUE COMPRENDE AMLODIPINA O SUS SALES FARMACEUTICAMENTE ACEPTABLES Y UN VEHICULO QUE EXCLUYE UN AGENTE ALCALINIZANTE QUE FORMA pH MAYOR QUE 5 DONDE LOS DOS COMPONENTES SE COMBINAN PARA FORMAR UNA COMPOSICION FINAL PARA DAR UNA FORMA DE DOSIFICACION SOLIDA. b) a second component comprising amlodipine or pharmaceutically acceptable salts thereof and a carrier EXCLUDES FORMING AN AGENT alkalizing pH greater than 5 where the two components are combined to form a final composition to give a dosage form SOLIDA. LA COMPOSICION FARMACEUTICA DONDE EL COMPONENTE (a) ES UNA GRANULACION HUMEDA Y EL COMPONENTE (b) ES UN COMPONENTE DE POLVO SECO; THE PHARMACEUTICAL COMPOSITION wherein component (a) is a wet granulation and component (b) is a component of DRY POWDER; Y EL AGENTE ALCALINIZANTE EN EL COMPONENTE (A) ES UN REGULADOR DE LA BIODISPONIBILIDAD Y MEJORADOR DE LA ESTABILIDAD. AND alkalizing agent in component (A) is a regulator of Bioavailability and improver stability. EL AGENTE ALCALINIZANTE SE SELECCIONA DE CARBONATO DE CALCIO, FOSFATO DE DICALCIO, FOSFATO DE TRICALCIO. Alkalizing agent selected from calcium carbonate, dicalcium phosphate, tricalcium phosphate. LA RELACION ENTRE ATORVASTATINA Y CARBONATO DE CALCIO ES DE 1:1 A 1:4 p/p. ATORVASTATIN AND THE RELATIONSHIP BETWEEN CALCIUM CARBONATE is 1: 1 to 1: 4 w / w. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION . ALSO it REFERS TO A process for the preparation. SE REFIERE TAMBIEN A UNA COMPOSICION QUE COMPRENDE AMLODIPINA, ATORVASTATINA Y UN VEHICULO QUE CONTIENE NO MAS DE 0,5% DE UN COMPUESTO SELECCIONADO DE ACIDO 5-(4-FLUOROFENIL)-2,3-DIHIDRO-ß,Ô-DIHIDROXI-3-(1-METILETIL)-2-OXO-4-FENIL-3-[(FENILAMINO)-CARBONIL]-1H-PIRROLO-1-HEPTANOICO, ENTRE OTROS. Also it refers to a composition comprising amlodipine, atorvastatin and a carrier containing not more than 0.5% of a compound selected of 5- (4-fluorophenyl) -2,3-dihydro-ß Ô-dihydroxy-3 - (1-methylethyl) -2-OXO-4-PHENYL-3 - [(phenylamino) carbonyl] -1H-pyrrole-1-heptanoic, and others. LA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE ANGINA DE PECHO, ATEROSCLEROSIS, HIPERTENSION The composition is useful for the treatment of angina pectoris, atherosclerosis, hypertension
PE0006662002A 2001-07-31 2002-07-25 pharmaceutical compositions of amlodipine and atorvastatin PE03242003A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US30913301P true 2001-07-31 2001-07-31

Publications (1)

Publication Number Publication Date
PE03242003A1 true PE03242003A1 (en) 2003-04-03

Family

ID=23196829

Family Applications (1)

Application Number Title Priority Date Filing Date
PE0006662002A PE03242003A1 (en) 2001-07-31 2002-07-25 pharmaceutical compositions of amlodipine and atorvastatin

Country Status (46)

Country Link
US (2) US20030114497A1 (en)
EP (2) EP1411923B1 (en)
JP (3) JP4020863B2 (en)
KR (2) KR20040032148A (en)
CN (2) CN1617717A (en)
AP (1) AP1745A (en)
AR (1) AR034925A1 (en)
AT (1) AT385793T (en)
AU (1) AU2002355680B2 (en)
BR (1) BR0211548A (en)
CA (1) CA2444554C (en)
CO (1) CO5540287A2 (en)
CR (1) CR7219A (en)
CY (1) CY1107245T1 (en)
DE (1) DE60225014T2 (en)
DK (1) DK1411923T3 (en)
DO (1) DOP2002000445A (en)
EA (1) EA006998B1 (en)
EC (1) ECSP044965A (en)
ES (1) ES2298381T3 (en)
GE (1) GEP20063926B (en)
GT (1) GT200200158A (en)
HN (1) HN2002000198A (en)
HR (1) HRP20040067A2 (en)
HU (1) HU0401569A2 (en)
IL (1) IL159440D0 (en)
IS (1) IS7089A (en)
MA (1) MA27052A1 (en)
MX (1) MXPA04000270A (en)
MY (1) MY137519A (en)
NI (1) NI200200095A (en)
NO (1) NO20040405L (en)
NZ (1) NZ530247A (en)
OA (1) OA13300A (en)
PA (1) PA8551701A1 (en)
PE (1) PE03242003A1 (en)
PL (1) PL368519A1 (en)
PT (1) PT1411923E (en)
RS (1) RS5304A (en)
SG (1) SG143982A1 (en)
SV (1) SV2003001189A (en)
TN (1) TNSN04022A1 (en)
UA (1) UA79750C2 (en)
UY (1) UY27402A1 (en)
WO (1) WO2003011283A1 (en)
ZA (1) ZA200400659B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524615B2 (en) * 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
CN1997651B (en) 2004-07-16 2012-06-06 力奇制药公司 Oxidative degradation products of atorvastatin calcium
KR100923939B1 (en) * 2004-09-28 2009-10-29 테바 파마슈티컬 인더스트리즈 리미티드 Process for preparing forms of atorvastatin calcium substantially free of impurities
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
WO2006059217A1 (en) * 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine besylate and processes for their preparation
US20080305158A1 (en) * 2004-12-28 2008-12-11 Ranbaxy Laboratories Limited Methods For the Preparation of Stable Pharmaceutical Solid Dosage Forms of Atorvastatin and Amlodipine
AU2006224161A1 (en) * 2005-03-15 2006-09-21 Lupin Limited Pharmaceutical compositions of amlodipine and benazepril
KR101381076B1 (en) * 2006-03-29 2014-04-02 코와 가부시키가이샤 Triglyceride-lowering agent and hyperinsulinism-ameliorating agent
DE102006033723A1 (en) * 2006-07-21 2008-01-24 Bayer Technology Services Gmbh Formulations of Multikompartimenten granules of active ingredients
KR100793321B1 (en) * 2006-11-29 2008-01-11 사회복지법인 삼성생명공익재단 Composition for treating or preventing olfactory disorder
CN101433539A (en) * 2007-11-12 2009-05-20 北京瑞康医药技术有限公司 Therapeutic compositions containing amlodipine niacin and rosuvastatin medicament
EP2070520A1 (en) * 2007-12-11 2009-06-17 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising at least one active agent and a binder, which swells in an acidic media
WO2009116061A2 (en) * 2008-01-10 2009-09-24 Alkem Laboratories Ltd. Stable oral pharmaceutical composition comprising atorvastatin
ES2377552T3 (en) 2008-09-17 2012-03-28 Bluepharma, Industria Farmaceutica, S.A. Easily dissolved and stable compositions of candesartan cilexetil prepared with a wet granulation
EP2341773A4 (en) * 2008-09-24 2012-03-07 Merck Sharp & Dohme Pharmaceutical compositions of atorvastatin
EP2575757A1 (en) * 2010-06-03 2013-04-10 Mahmut Bilgic Water soluble formulation comprising a combination of amlodipine and a statin
CN103945840A (en) 2011-08-26 2014-07-23 国立大学法人大阪大学 Prophylactic/therapeutic agent for cardiovascular complications of diabetes
JP2013231011A (en) * 2012-05-01 2013-11-14 Sawai Pharmaceutical Co Ltd Atorvastatin-containing pharmaceutical composition and orally disintegrating tablet using the same
KR20140028971A (en) 2012-08-31 2014-03-10 한미약품 주식회사 Bilayered tablet composite formulation of atorvastatin, irbesartan and magnesium carbonate
KR20140030505A (en) * 2012-08-31 2014-03-12 한미약품 주식회사 Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor
KR101771766B1 (en) * 2013-12-30 2017-08-28 알보젠코리아 주식회사 Pharmaceutical combination comprising Angiotensin-Ⅱ Receptor Blocker and HMG-CoA Reductase Inhibitor
KR20190084217A (en) 2019-06-26 2019-07-16 한미약품 주식회사 PHARMACEUTICAL COMPOSITE CAPSULE FORMULATION COMPRISING IRBESARTAN AND HMG-CoA REDUCTASE INHIBITOR

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) * 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) * 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5245047A (en) * 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) * 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) * 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (en) * 1989-07-21 1995-08-25 Warner Lambert Co Method pharmaceutically usable / R- (R *, R *) / - 2- (4-fluorophenyl) - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - / (phenylamino) carbonyl / -1 pyrrole-1-heptanoic acid and pharmaceutically acceptable salts thereof
US5248793A (en) * 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) * 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) * 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
AT178794T (en) * 1993-01-19 1999-04-15 Warner Lambert Co A stabilized composition comprising orally applicable procedure, the compound ci-981 and
US5385929A (en) * 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
SI9500173B (en) * 1995-05-19 2002-02-28 Lek, Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
ES2233526T3 (en) * 1995-07-17 2005-06-16 Warner-Lambert Company Llc hemicalcium of R- (R *, R *) ### -2 (4-fluorophenyl) -beta, delta-dihydroxy 5- (1-methylethyl) -3-phenyl-4 (phenylamino) carbonyl 1H-pyrrolo salt crystalline 1-heptanoic acid.
EP0858336B1 (en) * 1995-11-02 2006-12-20 Warner-Lambert Company Llc Method and pharmaceutical composition for regulating lipid concentration
GT199800127A (en) * 1997-08-29 2000-02-01 therapeutic combinations.
CN1117566C (en) * 1997-08-29 2003-08-13 辉瑞产品公司 Combination therapy comprising amlodipine and statin compound
GT199800126A (en) * 1997-08-29 2000-01-29 Combination therapy.
IL135154A (en) * 1997-11-25 2005-05-17 Warner Lambert Co Inhbition of lipoprotein oxidation
SK15382001A3 (en) * 1999-04-23 2002-05-09 R. Preston Mason Pharmaceutical composition comprising amlodipine, method of the treatment and method for reducing blood pressure
HN2000000050A (en) * 1999-05-27 2001-02-02 Pfizer Prod Inc mutual salt of amlodipine and atorvastatin
AU8308501A (en) * 2000-08-04 2002-02-18 R Preston Mason Synergistic effect of amlodipine and atorvastatin

Also Published As

Publication number Publication date
SG143982A1 (en) 2008-07-29
CR7219A (en) 2004-03-24
NI200200095A (en) 2004-06-07
AU2002355680B2 (en) 2007-11-15
TNSN04022A1 (en) 2006-06-01
CA2444554A1 (en) 2003-02-13
HN2002000198A (en) 2005-10-20
NZ530247A (en) 2006-06-30
IL159440D0 (en) 2004-06-01
MXPA04000270A (en) 2004-05-04
DE60225014T2 (en) 2008-06-12
UY27402A1 (en) 2003-02-28
EP1411923B1 (en) 2008-02-13
PA8551701A1 (en) 2003-02-14
KR100674762B1 (en) 2007-01-25
MY137519A (en) 2009-02-27
DOP2002000445A (en) 2003-01-31
HRP20040067A2 (en) 2005-02-28
AT385793T (en) 2008-03-15
JP4020863B2 (en) 2007-12-12
DE60225014D1 (en) 2008-03-27
UA79750C2 (en) 2007-07-25
US20030114497A1 (en) 2003-06-19
CA2444554C (en) 2007-09-04
GEP20063926B (en) 2006-09-25
OA13300A (en) 2007-04-13
DK1411923T3 (en) 2009-01-05
RS5304A (en) 2006-10-27
JP2007314566A (en) 2007-12-06
CO5540287A2 (en) 2005-07-29
ECSP044965A (en) 2004-03-23
PT1411923E (en) 2008-04-02
GT200200158A (en) 2003-05-15
US20050107446A1 (en) 2005-05-19
CN1617717A (en) 2005-05-18
WO2003011283A1 (en) 2003-02-13
JP2007153908A (en) 2007-06-21
KR20040032148A (en) 2004-04-14
NO20040405L (en) 2004-03-08
IS7089A (en) 2003-12-22
AR034925A1 (en) 2004-03-24
AP1745A (en) 2007-05-30
ES2298381T3 (en) 2008-05-16
KR20060054495A (en) 2006-05-22
MA27052A1 (en) 2004-12-20
PL368519A1 (en) 2005-04-04
HU0401569A2 (en) 2004-12-28
AP200402963A0 (en) 2004-03-31
EA006998B1 (en) 2006-06-30
CN101185646A (en) 2008-05-28
EP1411923A1 (en) 2004-04-28
EP1852116A1 (en) 2007-11-07
BR0211548A (en) 2004-07-13
JP2005501051A (en) 2005-01-13
SV2003001189A (en) 2003-03-18
ZA200400659B (en) 2005-04-28
CY1107245T1 (en) 2012-11-21
EA200400028A1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
TWI228050B (en) A pharmaceutical composition for use as HMG CoA reductase inhibitor and the production method thereof
CA2416685A1 (en) Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
TR199903034T2 (en) Piperazine derivatives and their use as anti-inflammatory agents.
BR0009830A (en) Compositions for skin care containing a combination of active substances for skin care
FR2780730B1 (en) Injectable compositions biphasic, particularly useful Reconstructive and Aesthetic Surgery
RU2001103136A (en) Inhibitors naladazy (naaladase), useful as pharmaceutical compounds and compositions
HU0003656A3 (en) Therapeutic combinations comprising amlodipin and atorvastatin
MXPA03010266A (en) Crystalline forms of 'r-(r*, r*)!-2 -(4-fluorophenyl)- beta, delta-dihydroxy -5-(1-methylethyl) -3-phenyl -4-'phenylamino)carbonyl !-1h-pyrrole -1-heptanoic acid calcium salt (2:1) (atorvastatin).
PA8436201A1 (en) 6,5-heterobicyclic derivatives substituted
NO965475D0 (en) Bioadhesive pharmaceutical composition for the controlled release of active substances
CY1111311T1 (en) New crystalline compound
ES2149761T3 (en) Pyridazinone derivative.
NO975320D0 (en) Pharmaceutical microdispersions comprising fluoro compounds
TR199902236T2 (en) "An N-piperidino-3-pyrazole carboxamide derivatives and pharmaceutical compositions for the oral administration of the salts thereof, and solvates"
SE9402431D0 (en) New Tablet Formulation
ES2187675T3 (en) (Methylsulfonyl) phenyl-2- (5H) -furanones as COX-2 inhibitors.
PL409305A1 (en) 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile and the pharmaceutical composition and their use
AR015524A1 (en) STABLE FORMULATION oxaliplatin solution, their use for the manufacture of a medicament, process for their preparation, pharmaceutical product containing it and a method for stabilizing a solution of oxaliplatin.
CY1113194T1 (en) Composition and antiviral activity producer ypokatestimenis azaindolooxooxikis PIPERAZINE
RS53895B1 (en) Modulators of atp-binding cassette transporters
CY1108833T1 (en) STABLE PHARMACEUTICAL PHARMACEUTICAL FORMS SOLUTION TO casting metrimenis DOSE INHALER DEVICES
NO20053645L (en) (4R) - and (4S) -diastereoisomerer of (2S) -2- [2-oxy-4-propylpyrrolidinyl] butanamide, and pharmaceutical compositions containing them
IT1235048B (en) Derived of 4h-benzopyran-4-one or a salt thereof, process for producing it and pharmaceutical composition containing it as an active ingredient
ECSP034831A (en) Substituted derivatives of 2-pyridine cyclohexane-1,4-diamine
ES2115237T3 (en) Phenyl heterocycles as inhibitors of cyclooxygenase-2.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed